ClinConnect ClinConnect Logo
Search / Trial NCT02296450

Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Nov 19, 2014

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Quality Of Life (Qo L) Assessment 14 236 Patients And Survivors

ClinConnect Summary

This clinical trial is looking at how skin conditions affect the overall quality of life for cancer patients and survivors. Many cancer patients experience skin problems either because of their cancer or as a side effect of treatments like chemotherapy or radiation. By asking patients to fill out questionnaires about how they feel about their skin conditions, the researchers hope to gain insights into these issues and find ways to improve treatment for skin conditions in cancer patients.

To participate in this study, you need to be a cancer patient or survivor who has a skin condition related to your cancer or its treatment. Patients must be at least 3 years old, and family members or caregivers can also help by providing consent for minors. Participants will complete a questionnaire about their skin condition initially and may fill it out again during a follow-up visit if they receive treatment. This study is currently recruiting participants and aims to deepen our understanding of the challenges faced by cancer patients dealing with skin issues.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Cancer patients and survivors with a pre-existing dermatologic condition related to their underlying disease or completed/ongoing therapy for cancer, who present for assessment/management of their skin condition.
  • Male or female patients at least 3 years and older
  • NOTE: Informed Consent guidelines will be followed for minors
  • First grade adult family members, spouses, and caregivers of patients with a Grade 2 or 3 or higher dermatologic condition related to their primary cancer or cancer treatment able to provide written informed consent
  • Exclusion Criteria:
  • Cognitive or psychiatric deficit resulting in an inability to provide written informed consent

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.

Locations

New York, New York, United States

Basking Ridge, New Jersey, United States

Harrison, New York, United States

Basking Ridge, New Jersey, United States

Hauppauge, New York, United States

Patients applied

0 patients applied

Trial Officials

Erica Lee, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials